Hong Kong – Sisram Medical Ltd. disclosed its Monthly Return for Equity Issuers for the period ended 31 March 2026, confirming no changes in either authorised or issued share capital during the month.

Authorised Share Capital • The company’s authorised ordinary share capital remained at 1.00 billion shares with a par value of ILS 0.01 each, equivalent to ILS 10.00 million. No increases or reductions were recorded.

Issued Shares and Treasury Stock • Issued shares (excluding treasury shares) stood unchanged at 468.34 million. • Sisram Medical held zero treasury shares, and there were no repurchases, cancellations, or transfers during the period.

Capital-Raising Instruments • The report shows no activity under share option schemes, warrants, convertibles, or other share-issuance arrangements for the month.

Public Float Status • The company affirmed compliance with the Hong Kong Main Board’s minimum public-float requirement of 25% of issued shares, ensuring sufficient free-float liquidity for investors.

Corporate Governance • The return was filed on 2 April 2026 by Company Secretary Qianli Fang, in accordance with Hong Kong Exchanges and Clearing Limited (HKEX) regulations.

With all key share capital metrics unchanged and full adherence to listing requirements, Sisram Medical closes March 2026 maintaining capital stability and regulatory compliance.